|
|
Article: PTH (1-34): a novel anabolic drug for the treatment of osteoporosis.(Review Article)
- Article from:
- Southern Medical Journal
- Article date:
- November 1, 2005
- Author:
CopyrightCOPYRIGHT 2005 Southern Medical Association. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abstract: The management of osteoporosis has in the past included providing patients with an adequate source of calcium and vitamin D and consideration of some type of antiresorption therapy such as hormone replacement, SERM therapy, or bisphosphonate therapy. However, patients who have very low bone density and continue to have fractures while receiving these therapies need to consider being treated with the recently approved novel anabolic drug PTH (1-34) (Forteo). The osteoblast has the receptor for parathyroid hormone (PTH). When PTH (1-34) is given in a pulsatile fashion, for example a daily subcutaneous injection, it stimulates osteoblasts to make new bone. PTH ...